PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 137 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,407 | +1169.2% | 195,756 | +957.3% | 0.04% | +720.0% |
| Q1 2023 | $426 | -31.6% | 18,515 | -67.6% | 0.01% | -37.5% |
| Q4 2022 | $623 | -99.9% | 57,121 | -43.0% | 0.01% | -20.0% |
| Q3 2022 | $845,000 | -30.2% | 100,200 | -34.5% | 0.01% | -23.1% |
| Q2 2022 | $1,210,000 | +55.1% | 153,033 | +364.3% | 0.01% | +116.7% |
| Q1 2022 | $780,000 | -40.8% | 32,959 | -14.5% | 0.01% | -14.3% |
| Q4 2021 | $1,318,000 | +284.3% | 38,550 | +99.1% | 0.01% | +250.0% |
| Q3 2021 | $343,000 | +172.2% | 19,366 | +589.2% | 0.00% | +100.0% |
| Q2 2021 | $126,000 | -44.2% | 2,810 | -67.8% | 0.00% | 0.0% |
| Q1 2021 | $226,000 | +113.2% | 8,725 | +61.0% | 0.00% | 0.0% |
| Q3 2020 | $106,000 | -51.2% | 5,420 | -55.8% | 0.00% | -50.0% |
| Q2 2020 | $217,000 | – | 12,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |